Objective and design: The use of proton pump inhibitors in acid-related diseases such as peptic ulcer or erosive reflux oesophagitis is well established. The aim of the current nationwide, multicentre ...

The benefit of reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) as salvage treatment for relapsing multiple myeloma (MM) Bortezomib (Bz) is a novel proteasome ...

RANIDO: A phase III clinical trial of racotumomab-alum or nimotuzumab versus docetaxel in advanced non-small cell lung cancer patients. Background: To date convincing clinical success with oncolytic ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Please provide your email address to receive an email when new articles are posted on . A 500 mg intramuscular injection of sotrovimab was noninferior to an IV infusion of the investigational ...

Please provide your email address to receive an email when new articles are posted on . DENVER — Subcutaneous administration of ocrelizumab showed similar safety and efficacy profiles to IV ...

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...

Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®. Subcutaneous (SC) administration of Opdivo (nivolumab) was not ...

The phase 3 IRAKLIA trial showed isatuximab's OBDS matches IV efficacy and pharmacokinetics, with fewer injection-site reactions. Subcutaneous isatuximab demonstrated a 71.1% objective response rate, ...